Dronedarone: A safety comparison to amiodarone

Current Drug Safety

Volumn 5, Issue 3, 2010, Pages 251-256

  Clem, James R ^a   Farver, Debra K ^a   Fischer, Janet R ^a   Johnson, Thomas J ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Amiodarone; Atrial fibrillation; Dronedarone; Safety; Sr 33589

Indexed keywords

AMIODARONE; CYTOCHROME P450; DIGOXIN; DRONEDARONE; MACROLIDE; MULTAQ; PLACEBO; QUINOLONE; UNCLASSIFIED DRUG; ANTIARRHYTHMIC AGENT; CREATININE;

ARTICLE; BRADYCARDIA; CARDIAC PATIENT; CLINICAL TRIAL; CORNEAL BIOPSY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; GASTROENTERITIS; HEADACHE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFECTION; INSOMNIA; LUNG TOXICITY; MORTALITY; NAUSEA; NONHUMAN; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SKIN DISCOLORATION; TORSADE DES POINTES; TREATMENT DURATION; VOMITING; ANALOGS AND DERIVATIVES; ANIMAL; ATRIAL FIBRILLATION; BLOOD; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG APPROVAL; DRUG INTERACTION; FOOD AND DRUG ADMINISTRATION; UNITED STATES;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; CREATININE; DRUG APPROVAL; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77954670078     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610791698280     Document Type: Article

References (36)

1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation- executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: 3257-e354.
2. Goldschlager N, Epstein AE, Naccarelli G, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007; 4: 1250-9.
3. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007; 356: 935-41.
4. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence- based review of clinical indications. JAMA 2007; 298: 1312-22.
5. Sablayrolles S, Le Grand B. Drug evaluation: dronedarone, a novel non-iodinated antiarrhythmic agent. Curr Opin Investig Drugs 2006; p907: 842-9.
6. Tafreshi MJ, Rowles J. A review of the investigational antiarrhythmic agent dronedarone. J Cardiovasc Pharmacol 2007; 12: 15-26.
7. Kathofer S, Thomas D, Karle CA. The novel drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev 2005; 23: 217-30.
8. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003; 91: 15D-26D.
9. FDA News: FDA advisory committee recommends approval of Multaq (dronedarone). Sanofi Aventis U.S. LLC.[cited 2009 March 18]. Available from: http://www.sanofi-aventis.us/live/us/ medias/83D126BC-EDDE-4C77-B4B4-64AE05EB1312.pdf
10. Wadhani N, Sarma JSM, Singh BN, Radzik D, Gaud C. Dose-dependent effects of oral dronedarone on the circadian variation of RR and QT intervals in healthy subjects. J Cardiovasc Pharmacol Ther 2006; 11: 184-90.
11. European Medicines Agency. Withdrawal public assessment report of the marketing authorization application for Multaq (droned- arone). Available from: http://www.emea.europa.eu/humandocs/PD Fs/EPAR/multaq/361489en4.pdf. [Accessed February 26, 2009].
12. Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother 2007; 41: 599-605.
13. Singh BN, Connolly SJ, Crijns HJGM, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation. N Engl J Med 2007; 357: 987-99.
14. Davy J, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008; 156(527): 1-9.
15. Hohnloser SH, Crijns HJGM, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-78.
16. Flaharty KK, Chase SL, Yaghsezian HM, Rubin R. Hepatotoxicity associated with amiodarone therapy. Pharmacotherapy 1989; 9: 39-44.
17. Foley P, Kalra P, Andrews N. Amiodarone: avoid the danger of Torsades de Pointes. Resuscitation 2008; 76: 137-41.
18. Cordarone (amiodarone) package Insert. Wyeth. [cited 18 March 2009] http://www.wyeth.com/content/showlabeling.asp?id=93
19. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005; 118: 706-14.
20. Robinson K, Mulrow JP, Rowland E, McKenna WJ. Long-term effects of amiodarone on hepatic function. Am J Card 1989; 64: 95-6.
21. London A, Albers JW. Toxic neuropathies associated with pharmaceutic and industrial agents. Neuro Clin 2007; 25: 257-76.
22. D'Amico DJ, Kenyon KR, Ruskin JN. Amiodarone keratopathy: drug-induced lipid storage disease. Arch Ophthalmol 1981; 99: 257-61.
23. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Safety 2008; 31: 127-41.
24. Mindel JS. Amiodarone and optic neuropathy. Am Heart J 2008; 156: 411-3.
25. Murphy MA, Murphy JF. Amiodarone and optic neuropathy: the heart of the matter. J Neuro-Ophthalmol 2005; 25: 232-6.
26. Camus P, Martin II WJ, Rosenous III EC. Amiodarone pulmonary toxicity. Clin Chest Med 2004; 25: 65-75.
27. Køber L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678-87.
28. Touboul P, Brugada J, Capucci A, Crijns HJGM, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose ranging study. Eur Heart J 2003; 24: 1481-7.
29. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007; 64: 785-91.
30. Multaq (dronedarone) package insert. Sanofi-Aventis. [cited 20 October 2009]. Available from: http://products.sanofi-aventis.us/ multaq/multaq.html
31. th ed. In: Brunton LL, Lazo JS, Parker KL Eds. McGraw-Hill: New York 2006; pp. 899-932.
32. Fenster PE, White NW, Hanson CD. Pharmacokinetic evaluation of the digoxin-amiodarone interaction. J Am Coll Cardiol 1985; 5: 108-12.
33. Nademanee K, Kannan R, Hendrickson J, Ookhtens M, Kay I, Singh BN. Amiodarone-digoxin interaction: Clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol 1984; 4: 111-6.
34. Robinson K, Johnston A, Walker S, Mulrow JP, McKenna WJ, Holt DW. The digoxin-amiodarone interaction. Cardiovasc Drugs Ther 1989; 3: 25-8.
35. Santostasi G, Fantin M, Maragno I, Gaion RM, Basadonna O, Dalla-Volta S. Effects of amiodarone on oral and intravenous digoxin kinetics in health subjects. J Cardiovasc Pharmacol 1987; 9: 385-90.
36. Damy T, Pousset F, Caplain H, Hulot J-S, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers in healthy subjects. Fundam Clin Pharmacol 2004; 18: 113-23.